Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylic Acid SCHEMBL10461112 | 0.92 | LMNA (0.39) | GRIK1GRIK2CYP2C9 | |
| SCHEMBL8173111 | 0.87 | ALOX15 (0.32) | — | |
| SCHEMBL5936787 | 0.84 | GRIK1 (0.35) | GRIK1GRIK2 | |
| SCHEMBL5936788 | 0.84 | GRIK1 (0.35) | GRIK1GRIK2 | |
| SCHEMBL10875230 | 0.83 | GRIK1 (0.38) | GRIK1GRIK2CYP2C9 | |
| SCHEMBL4740580 | 0.80 | GABRR1 (0.41) | CYP2C9 | |
| SCHEMBL1659416 | 0.79 | EP300 (0.46) | GRIK1CYP2C9 | |
| SCHEMBL8622691 | 0.79 | CYP2C9 (0.39) | GRIK1GRIK2CYP2C9PTGS1AKR1C3 | |
| SCHEMBL8743386 | 0.78 | CYP2C9 (0.33) | CYP2C9 | |
| SCHEMBL17817 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340519-A9 | DUAL-CHAMBER PACK FOR EXTENDED RELEASE SUSPENSION COMPOSITIONS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-11-30 | — | — | US | claimed |
| EP-1648421-B1 | ORALLY DISSOLVING FILMS | GLAXOSMITHKLINE LLC (US) | 2017-10-18 | — | — | EP | claimed |
| US-9675548-B2 | Orally dissolving films | GlaxoSmithKline, LLC (US) | 2017-06-13 | — | — | US | claimed |
| US-20170119627-A1 | DUAL-CHAMBER PACK FOR EXTENDED RELEASE SUSPENSION COMPOSITIONS | SUN PHARMACEUTICAL IND LTD (IN) | 2017-05-04 | — | — | US | claimed |
| US-20160228379-A1 | EXTENDED RELEASE SUSPENSION COMPOSITIONS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-08-11 | — | — | US | claimed |
| EP-2446881-A1 | Orally Dissolving Films | Glaxosmithkline LLC (US) | 2012-05-02 | — | — | EP | claimed |
| EP-1648421-A4 | ORALLY DISSOLVING FILMS | SMITHKLINE BEECHAM CORP (US) | 2009-08-26 | — | — | EP | claimed |
| US-20060198873-A1 | Orally dissolving films | HALEON US HOLDINGS LLC | 2006-09-07 | — | — | US | claimed |
| EP-1648421-A2 | ORALLY DISSOLVING FILMS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005009386-A2 | ORALLY DISSOLVING FILMS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-12012418-B2 | Aryl receptor modulators and methods of making and using the same | NOGRA PHARMA LIMITED (IE) | 2024-06-18 | — | — | US | disclosed |
| EP-4355344-A1 | PROBIOTIC COMPOSITIONS FOR ALLEVIATING GASTROINTESTINAL SYMPTOMS IN SUBJECTS WITH A NEUROLOGICAL DISORDER | Biohm Health Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-4341403-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | Nogra Pharma Limited (IE) | 2024-03-27 | — | — | EP | disclosed |
| US-20240093197-A1 | IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME | NOGRA PHARMA LIMITED (IE) | 2024-03-21 | — | — | US | disclosed |
| EP-3160964-B1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | NOGRA PHARMA LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| US-4447525-A | Process for providing a matt surface on a photographic material and photographic material provided with such matt surface | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1984-05-08 | — | — | US | disclosed |
| EP-0075231-A2 | Process for providing a matt surface on a photographic material and photographic material provided with such matt surface | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1983-03-30 | — | — | EP | disclosed |
| US-4342672-A | Use of Heteropolysaccharide S-156 in latex paint | MERCK & CO., INC. (US) | 1982-08-03 | — | — | US | disclosed |
| US-4298691-A | CULTURE OF DLEBSIELLA VARIANT | MERCK & CO., INC. (US) | 1981-11-03 | — | — | US | disclosed |
| US-4155887-A | POROUS PARTICLES, POLYSACCHARIDE, FILLER IN AQUEOUS DISPERSION | HETSON GEORGE W | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060198873-A1 | Orally dissolving films | TAS2R16, TAS2R7, TAS2R30 | GRIK1 848/4885GRIK2 827/4885CYP2C9 320/4885 |
| US-12012418-B2 | Aryl receptor modulators and methods of making and using the same | AHR, IL23R, IL2RA | GRIK1 2652/4885GRIK2 1747/4885CYP2C9 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.